Zotepine
Modify Date: 2025-08-25 11:10:26
Zotepine structure
|
Common Name | Zotepine | ||
|---|---|---|---|---|
| CAS Number | 26615-21-4 | Molecular Weight | 331.86 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 478.4±45.0 °C at 760 mmHg | |
| Molecular Formula | C18H18ClNOS | Melting Point | 90-91 °C | |
| MSDS | Chinese USA | Flash Point | 243.2±28.7 °C | |
| Symbol |
GHS07, GHS09 |
Signal Word | Warning | |
Use of ZotepineZotepine, an antipsychotic agent, is a potent antagonist of 5-HT2A, 5-HT2C, Histamine H1, α1-adrenergic and Dopamine D2 receptors, with Kds of 2.6 nM, 3.2 nM, 3.3 nM, 7.3 nM and 8 nM, respectively. Zotepine exhibits antidepressive and anxiolytic effects in vivo[1][2]. |
| Name | zotepine |
|---|---|
| Synonym | More Synonyms |
| Description | Zotepine, an antipsychotic agent, is a potent antagonist of 5-HT2A, 5-HT2C, Histamine H1, α1-adrenergic and Dopamine D2 receptors, with Kds of 2.6 nM, 3.2 nM, 3.3 nM, 7.3 nM and 8 nM, respectively. Zotepine exhibits antidepressive and anxiolytic effects in vivo[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Zotepine shows multiple antagonistic profiles with strong affinities to α1-adrenergic, α2-adrenergic, Dopamine D2, Histamine H1, Muscarinic, 5-HT1A, 5-HT1D, 5-HT2A, and 5-HT2C receptors, with Kds of 7.3, 180, 8, 3.3, 330, 280, 80, 2.6, 3.2 nM, respectively[1]. |
| In Vivo | Zotepine (1-3 mg/kg; a single i.p.) dose-dependently increases noradrenaline, dopamine, GABA, and glutamate release without affecting 5-HT levels in the medial prefrontal cortex of rats[2]. Animal Model: Male Sprague-Dawley rats (250-300 g)[1] Dosage: 1, 3 mg/kg Administration: A single i.p. Result: Increased noradrenaline, dopamine, GABA, and glutamate release without affecting 5-HT levels in the medial prefrontal cortex. Increased neuronal firing frequencies in the VTA, DRN, LC and MTN in a dose-dependent manner. |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 478.4±45.0 °C at 760 mmHg |
| Melting Point | 90-91 °C |
| Molecular Formula | C18H18ClNOS |
| Molecular Weight | 331.86 |
| Flash Point | 243.2±28.7 °C |
| Exact Mass | 331.079773 |
| PSA | 37.77000 |
| LogP | 6.57 |
| Vapour Pressure | 0.0±1.2 mmHg at 25°C |
| Index of Refraction | 1.656 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
|
Safety evaluation of zotepine for the treatment of schizophrenia.
Expert Opin. Drug Saf. 9(4) , 659-66, (2010) Atypical antipsychotics have become the first-line treatment for patients suffering from schizophrenia in the industrialized world. Given the frequent necessity of a life-long enduring antipsychotic t... |
|
|
Zotepine for schizophrenia.
Cochrane Database Syst. Rev. (4) , CD001948, (2006) Zotepine is a relatively new antipsychotic often used for the treatment of people with schizophrenia. It is claimed to be particularly effective for negative symptoms.To determine the effects of zotep... |
|
|
Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients.
Neuro Endocrinol. Lett. 28(6) , 881-8, (2007) The main objective was to evaluate the effect of five second-generation antipsychotics (amisulpride, quetiapine, olanzapine, risperidone, and zotepine) on prolactinaemia during 6 week therapy in 433 f... |
| Nipolept |
| UNII-U29O83JAZW |
| Zotepina |
| Zotepine |
| 2-[(8-Chlorodibenzo[b,f]thiepin-10-yl)oxy]-N,N-dimethylethanamine |
| 2-Chloro-11-(2-dimethylaminoethoxy)dibenzo[b,f]thiepine |
| Setous |
| 2-(3-chlorobenzo[b][1]benzothiepin-5-yl)oxy-N,N-dimethylethanamine |
| Zoleptil |
| Compound-4 |
| Zotepinum |
| Ethanamine, 2-[(8-chlorodibenzo[b,f]thiepin-10-yl)oxy]-N,N-dimethyl- |
| Lodopin |